92 related articles for article (PubMed ID: 22566536)
1. Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development.
Peters SA; Schroeder PE; Giri N; Dolgos H
Drug Metab Dispos; 2012 Aug; 40(8):1495-507. PubMed ID: 22566536
[TBL] [Abstract][Full Text] [Related]
2. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
Guest EJ; Rowland-Yeo K; Rostami-Hodjegan A; Tucker GT; Houston JB; Galetin A
Br J Clin Pharmacol; 2011 Jan; 71(1):72-87. PubMed ID: 21143503
[TBL] [Abstract][Full Text] [Related]
3. Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.
Boulenc X; Barberan O
Drug Metabol Drug Interact; 2011; 26(4):147-68. PubMed ID: 22149659
[TBL] [Abstract][Full Text] [Related]
4. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.
Guest EJ; Aarons L; Houston JB; Rostami-Hodjegan A; Galetin A
Drug Metab Dispos; 2011 Feb; 39(2):170-3. PubMed ID: 21036951
[TBL] [Abstract][Full Text] [Related]
5. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors.
Wang YH
Drug Metab Dispos; 2010 Jul; 38(7):1094-104. PubMed ID: 20368327
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
Grime KH; Bird J; Ferguson D; Riley RJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
[TBL] [Abstract][Full Text] [Related]
7. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different approaches to predict metabolic drug-drug interactions.
Einolf HJ
Xenobiotica; 2007; 37(10-11):1257-94. PubMed ID: 17968745
[TBL] [Abstract][Full Text] [Related]
9. Application of mechanism-based CYP inhibition for predicting drug-drug interactions.
Zhou ZW; Zhou SF
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):579-605. PubMed ID: 19466877
[TBL] [Abstract][Full Text] [Related]
10. Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk.
Shardlow CE; Generaux GT; MacLauchlin CC; Pons N; Skordos KW; Bloomer JC
Drug Metab Dispos; 2011 Nov; 39(11):2076-84. PubMed ID: 21832001
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interaction prediction assessment.
Zhou J; Qin Z; Sara QK; Kim S; Wang Z; Hall SD; Li L
J Biopharm Stat; 2009 Jul; 19(4):641-57. PubMed ID: 20183431
[TBL] [Abstract][Full Text] [Related]
12. Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.
Feng B; Hurst S; Lu Y; Varma MV; Rotter CJ; El-Kattan A; Lockwood P; Corrigan B
Mol Pharm; 2013 Nov; 10(11):4207-15. PubMed ID: 24066726
[TBL] [Abstract][Full Text] [Related]
13. Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
Gomez-Mantilla JD; Huang F; Peters SA
Clin Pharmacokinet; 2023 Mar; 62(3):457-480. PubMed ID: 36752991
[TBL] [Abstract][Full Text] [Related]
14. Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
Iga K
J Pharm Sci; 2015 Oct; 104(10):3565-77. PubMed ID: 26099559
[TBL] [Abstract][Full Text] [Related]
15. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.
Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
Drug Metab Dispos; 2011 Apr; 39(4):591-602. PubMed ID: 21212240
[TBL] [Abstract][Full Text] [Related]
16. Risk assessment of drug-drug interactions using hepatocytes suspended in serum during the drug discovery process.
Kosugi Y; Hirabayashi H; Igari T; Fujioka Y; Okuda T; Moriwaki T
Xenobiotica; 2014 Apr; 44(4):336-44. PubMed ID: 24074236
[TBL] [Abstract][Full Text] [Related]
17. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
McGinnity DF; Waters NJ; Tucker J; Riley RJ
Drug Metab Dispos; 2008 Jun; 36(6):1126-34. PubMed ID: 18356267
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.
Duan JZ; Jackson AJ; Zhao P
J Clin Pharmacol; 2011 Jul; 51(7):1087-100. PubMed ID: 20864622
[TBL] [Abstract][Full Text] [Related]
19. Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution.
Kirby BJ; Unadkat JD
Drug Metab Dispos; 2010 Nov; 38(11):1926-33. PubMed ID: 20724498
[TBL] [Abstract][Full Text] [Related]
20. Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.
Ito K; Sugiyama Y
Trends Pharmacol Sci; 2010 Aug; 31(8):351-5. PubMed ID: 20542578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
